Beacon VP Investments
Contributor since: 2012
Company: Beacon vp investments
AveXis's AVXS-101 Phase I Trial Results Likely To Indicate Future Success
Acadia: Approval Likely For Parkinson's Disease Psychosis Drug
Chiasma's Mycapssa For Acromegaly Treatment Is Likely To Receive FDA Approval
OPKO's Rayaldee: Likely Approval For A Kidney Disease Game Changer
Eteplirsen For Duchenne Muscular Dystrophy Should Receive FDA Accelerated Approval
BioDelivery Sciences International's Drug Belbuca Likely To Receive FDA Approval
The Medicines Company: Raplixa Approval Is Likely, Manufacturing Risk Is Low
Avanir's Drug-Device Combo Experiencing Minor FDA Headaches
Enanta And AbbVie's ABT-450 Likely To Receive FDA Approval
Exact Sciences' Stool-DNA-Based Colorectal Cancer Screening Test Likely To Get Favorable Review On Its PMA
Antares' Otrexup Ready For FDA Approval
Safety Concerns May Prevent FDA Approval Of Ligand's Drug Aprela
Anacor's Drug Tavaborole Should Receive FDA Approval
Keryx Biopharmaceuticals' Zerenex Likely To Receive FDA Approval
AP Pharma's Drug Likely To Receive FDA Approval
Theravance's Drug Breo Likely To Receive FDA Approval
Depomed's Drug Serada Ready For FDA Approval
MAP's Levadex Ready For FDA Approval
Raptor's Drug Procysbi Ready For FDA Approval
Hyperion's Drug Ravicti Likely To Receive FDA Approval
Hemispherx's Ampligen Is Unlikely To Receive FDA Approval
Alexza's Adasuve May Not Be Ready For FDA Approval
Exelixis's Cabozantinib Should Receive FDA Approval, But Faces Long-Term Challenges
Despite Safety Concerns, Dynavax's Heplisav Should Receive FDA Approval
Aegerion's Drug Lomitapide Should Receive FDA Approval